Omnicell (NASDAQ:OMCL) Shares Down 4.6% – Here’s Why

Omnicell, Inc. (NASDAQ:OMCL) shares fell 4.6% during mid-day trading on Tuesday . The stock traded as low as $42.52 and last traded at $43.1340. 608,322 shares changed hands during trading, a decline of 4% from the average session volume of 634,329 shares. The stock had previously closed at $45.22.

Analysts Set New Price Targets

OMCL has been the topic of a number of analyst reports. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Wells Fargo & Company boosted their target price on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. KeyCorp boosted their price objective on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Finally, Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $59.86.

Omnicell Stock Down 2.3%

The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of 92.87, a price-to-earnings-growth ratio of 1.08 and a beta of 0.96. The firm’s 50-day simple moving average is $42.53 and its 200-day simple moving average is $41.44.

Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter last year, the company earned $0.26 earnings per share. The firm’s revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Sell-side analysts forecast that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Omnicell

Hedge funds have recently made changes to their positions in the business. Handelsbanken Fonder AB lifted its holdings in shares of Omnicell by 18.3% during the 2nd quarter. Handelsbanken Fonder AB now owns 12,923 shares of the company’s stock worth $537,000 after acquiring an additional 2,000 shares during the period. Versant Capital Management Inc increased its stake in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after acquiring an additional 294 shares during the period. Empowered Funds LLC increased its stake in Omnicell by 4,229.9% in the first quarter. Empowered Funds LLC now owns 262,043 shares of the company’s stock valued at $8,747,000 after acquiring an additional 255,991 shares during the period. Bank of America Corp DE raised its position in Omnicell by 31.3% in the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock worth $19,390,000 after purchasing an additional 138,537 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in Omnicell by 14.2% during the first quarter. California State Teachers Retirement System now owns 50,323 shares of the company’s stock worth $1,680,000 after purchasing an additional 6,273 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.